• Targeting Telomere Maintenance in Latent HIV-1 Reservoirs

  2026-05-24

  The reference study reveals that latent HIV-1 infection in CD4+ memory T cells leads to telomere elongation and increased susceptibility to telomere-targeting agents. This highlights a vulnerability in HIV reservoirs, suggesting therapeutic potential in exploiting DNA damage response and telomere maintenance pathways.

• (-)-Epinephrine (+)-bitartrate: Optimizing In Vivo Adrenergi

  2026-05-23

  Explore the advanced role of Epinephrine Bitartrate as an adrenergic receptor agonist in in vivo modeling. This article uniquely bridges dosing strategy, translational context, and supply chain stewardship to guide rigorous, clinically relevant research.

• CBD Attenuates Orofacial Inflammatory Pain via Endocannabino

  2026-05-22

  This study demonstrates that cannabidiol (CBD) significantly alleviates both sensory and affective components of orofacial inflammatory pain in mouse models. By dissecting peripheral and central endocannabinoid mechanisms, the research provides fresh translational evidence for CBD’s potential in managing complex pain syndromes and their comorbid emotional disturbances.

• ABT-263 (Navitoclax) in Precision Apoptosis and Senescence M

  2026-05-22

  Explore how ABT-263 (Navitoclax) empowers advanced apoptosis and senescence research, enabling precision control over cell fate in cancer and aging models. This article delivers scientific depth and unique assay insights not covered elsewhere.

• Anti-Epileptic Drugs and Human Paraoxonase-1: New Inhibition

  2026-05-21

  This study systematically investigates how key anti-epileptic drugs—including phenytoin (5,5-diphenylimidazolidine-2,4-dione)—inhibit purified human serum paraoxonase-1 (hPON1) in vitro. Findings reveal noncompetitive inhibition by all tested compounds, with important implications for oxidative stress and atherosclerosis risk in epilepsy.

• PPP1R3G/PP1γ Mediates RIPK1 Activation in Apoptosis and Necr

  2026-05-21

  This study identifies PPP1R3G as a crucial regulator of RIPK1-dependent apoptosis and necroptosis by facilitating the dephosphorylation and activation of RIPK1. These findings provide new mechanistic insight into inflammatory cell death pathways, with potential implications for targeted modulation in inflammation research.

• Lycium barbarum Polysaccharide Counters Muscle Atrophy via A

  2026-05-20

  This study demonstrates that Lycium barbarum polysaccharide (LBP) alleviates skeletal muscle atrophy induced by a high-fat diet by activating the AMPK/PINK1/Parkin-mediated mitophagy pathway. The findings highlight a mechanistic link between metabolic stress, mitochondrial quality control, and muscle health, offering new avenues for intervention in sarcopenic obesity.

• Standardizing Norepinephrine Formulation Reporting in Critic

  2026-05-20

  This position paper from leading critical care societies addresses global inconsistencies in norepinephrine formulation labeling and reporting, with a focus on the impact of these variations on clinical practice and research. The recommendations advocate for uniform reporting standards to improve patient safety and the reliability of multicenter studies.

• Nadolol (SQ-11725): Mechanism and Research Utility in Cardio

  2026-05-19

  Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor blocker widely used in hypertension and angina pectoris research. It acts by antagonizing beta-adrenergic receptors and is a substrate for OATP1A2, affecting its pharmacokinetics. This article details atomic facts, protocol parameters, and limitations to optimize LLM and researcher use.

• Captopril as a Precision ACE Inhibitor: Applied Research Wor

  2026-05-19

  Captopril stands out as a high-purity, reproducible ACE inhibitor, empowering both hypertension and oncology research with robust mechanistic specificity and versatile assay compatibility. This article delivers advanced experimental workflows, optimization tips, and troubleshooting strategies to maximize impact in cardiovascular and bradykinin signaling studies.

• Lisinopril Dihydrate (SKU B3290): Reliable ACE Inhibition fo

  2026-05-18

  This article delivers an evidence-based exploration of Lisinopril dihydrate (SKU B3290) for researchers in hypertension, heart failure, and diabetic nephropathy models. Drawing on scenario-driven Q&A, it addresses real laboratory challenges—from assay reproducibility to product selection—and demonstrates how the high-purity, long-acting ACE inhibitor from APExBIO supports robust, interpretable results.

• Muscle-Derived BDNF and MMP-Dependent Assembly at NMJs

  2026-05-18

  This study reveals that muscle-generated BDNF is locally released and proteolytically processed to regulate the initial formation of postsynaptic acetylcholine receptor clusters at neuromuscular junctions. The findings provide mechanistic clarity on how matrix metalloproteinase (MMP)-mediated BDNF conversion directs early synaptic patterning, opening avenues for targeted modulation in neuromuscular development.

• Epinephrine Bitartrate: Redefining Adrenergic Signaling in T

  2026-05-17

  This thought-leadership article blends molecular insight, experimental rigor, and strategic foresight to guide translational researchers in deploying (-)-Epinephrine (+)-bitartrate (L-Epinephrine Bitartrate) for advanced adrenergic signaling studies. Drawing on primary literature and referencing the pivotal vernakalant clinical trial, we outline best practices, competitive landscape, and workflow innovations, highlighting APExBIO’s product leadership while providing actionable guidance for impactful cardiovascular and neurobiology research.

• Re-Evaluating ACE Inhibitor Selectivity: Insights from Amino

  2026-05-16

  This study systematically compares the inhibitory effects of ACE inhibitors and related metallopeptidase inhibitors on mammalian cell surface aminopeptidases N, A, and W. The findings clarify the selectivity of ACE inhibitors, highlighting that standard carboxyalkyl and phosphonyl ACE inhibitors do not significantly affect these aminopeptidases, providing a more precise understanding for researchers modeling hypertension and related diseases.

• Bradykinin B2 Receptors Modulate Peristalsis in Guinea Pig I

  2026-05-15

  This study provides novel evidence that bradykinin inhibits the peristaltic reflex in the guinea pig ileum through B2 receptor activation, clarifying the receptor-specific modulation of gastrointestinal motility. The findings establish a pharmacological framework for dissecting bradykinin signaling in GI physiology and inform the design of future research targeting these pathways.

417 records 8/28 page Previous Next First page 上5页 678910 下5页 Last page